Key Points {#FPar1}
==========

Evidence supporting the use of biosimilar epoetins has been acquired over more than 10 years since first approval in Europe.Based on the available evidence and experience, nephrologists can be reassured that these medicines offer high-quality, affordable and effective alternatives to existing reference medicines used to treat renal anemia.

Introduction {#Sec1}
============

Patients with chronic kidney disease (CKD) are at increased risk of anemia. In a study in the USA, anemia was twice as prevalent in patients with CKD (15.4%), compared with the general population (7.6%); the prevalence increased from 8.4% with CKD stage 1 to 53.4% with stage 5 \[[@CR1]\]. Importantly, anemia in patients with CKD is associated with increased risk of health-related quality of life (HRQoL) impairment, cardiovascular disease, hospitalization, end-stage renal disease, and mortality, compared with CKD patients without anemia \[[@CR2], [@CR3]\]. Furthermore, direct healthcare costs are higher in CKD patients with anemia than in those without \[[@CR4]\].

The introduction of recombinant human erythropoietin into clinical practice in the 1980s was a breakthrough in the treatment of renal anemia \[[@CR5]\]. Initially, use of recombinant erythropoietin was limited to dialysis patients with the most severe forms of anemia; however, its use was subsequently extended to most dialysis patients with renal anemia and to predialysis patients, but only in countries in which the high cost of treatment did not limit access \[[@CR5]\]. Following expiry of the European patent for the recombinant human erythropoietin, epoetin alfa, several biosimilar epoetins have been developed for the European market and licensed for use in the nephrology setting. Biosimilars are biological medicines that are approved via stringently defined regulatory pathways on the basis that comparable safety, efficacy, and quality has been demonstrated to their reference medicine. The advantage of biosimilar drugs is that they are less expensive than the reference medicine, allowing for greater patient access and cost savings in already stretched healthcare budgets \[[@CR6]\]. This review outlines the regulatory process and requirements for biosimilar development and approval, discusses initial concerns raised about epoetin biosimilars by the nephrology community, describes clinical evidence gained, and discusses what can be learned from the European experience.

Pathway for Development and Approval of Biosimilars {#Sec2}
---------------------------------------------------

Development, manufacture, and approval pathways are very different for biosimilars, compared with small-molecule generics, particularly as biological medicines (including biosimilars) are more complex molecules. The European Medicines Agency (EMA) was the first regulatory authority to establish legislative procedures for the approval of biosimilars when they published guidance in 2005 \[[@CR7]\]. The EMA regulatory pathway for the approval of biosimilars is based on demonstrating comparable quality, safety, and efficacy to the reference medicine (Table [1](#Tab1){ref-type="table"}) \[[@CR8], [@CR9]\]. The EMA have also issued guidelines for specific product classes, including biosimilar epoetins \[[@CR10]\].Table 1Key points from the general EMA guidance for biosimilars \[[@CR7], [@CR8]\]Definition of a biosimilarA biological medicinal product that contains a version of the active substance of an already authorized original biological medicine (reference medicinal product) in the EEA. Similarity to the reference medicinal product needs to be established based on a comprehensive comparability exercise (taking account of quality characteristics, biological activity, safety, and efficacy)Choice of reference medicinal productMust be a medicinal product authorized in the EEA, on the basis of a complete dossier in accordance with the provisions of Article 8 of Directive 2001/83/EC, as amended\
 In some cases, it may be possible to compare the biosimilar in certain clinical and non-clinical studies with a non-EEA authorized medicinal product. The aim of this is to facilitate the global development of biosimilars and avoid unnecessary repetition of clinical trialsNon-clinical studies1. *In vitro* studies\
 Data from several comparative studies should normally be provided in order to assess any potential differences in biological activity between the biosimilar and reference medicinal product\
 Studies should cover the entire spectrum of pharmacological and toxicological aspects\
 Studies should include relevant assays on:\
  Binding to target(s), for example, receptors known to be involved in the pharmacological effects of the reference medicine\
  Signal transduction and functional activity/viability of cells known to be of relevance for the pharmaco-toxicological effects of the reference medicine and for the product class\
 *In vitro* assays are often more specific and sensitive to detect differences between a biosimilar and reference medicine than animal studies; therefore, these assays can be considered as most important for the non-clinical biosimilar comparability exercise2. Determination of the need for *in vivo* studies\
 Factors to consider when assessing the need for *in vivo* non-clinical studies include:\
  Presence of potentially relevant quality attributes that have not been detected in the reference medicine, such as new post-translational modifications\
  Presence of potentially relevant quantitative differences in quality attributes between the biosimilar and the reference medicine\
  Relevant differences in formulation, such as use of excipients not widely used for biotechnology-derived proteins3. *In vivo* studies\
 If these are deemed necessary, the focus (PK and/or PD and/or safety) depends on the additional information that is neededClinical studiesIt is recommended that the clinical data required for the biosimilar comparability exercise are generated using the biosimilar product derived from the commercial manufacturing process1. PK/PD studies\
 Comparative studies designed to demonstrate similar PK profile of the biosimilar and reference medicine are a key part of the biosimilar development program\
 Single-dose studies that fully characterize the PK profile are preferable\
 If the reference product can be administered IV and SC, evaluation of SC administration will usually be sufficient (as this covers absorption and elimination)\
 PD markers, selected on the basis of clinical relevance to the clinical outcome, should be added to the PK studies whenever feasible2. Efficacy studies\
 Study populations should be representative of approved therapeutic indications of the reference medicine and be sensitive for detecting potential differences between the biosimilar and the reference\
 Equivalence study designs are preferred. Use of a non-inferiority design must be discussed with the regulatory authorities and justified with a strong scientific rationale\
 Studies are not intended to demonstrate the efficacy of a biosimilar *per se* (this has already been shown for the reference medicine); the purpose is to confirm comparable clinical performance of the biosimilar and the reference medicine3. Clinical safety\
 Data should be captured during PK/PD studies as well as in pivotal clinical efficacy studies\
 Immunogenicity testing of the biosimilar and reference medicine should use the same assay format and sampling schedule. The incidence and nature of antibodies and antibody titers should be assessed and interpreted in relation to potential effects on clinical efficacy and safetyExtrapolation of indications When biosimilarity has been shown in one indication, extrapolation of clinical data to other indications of the reference medicine is possible but needs to be scientifically justified\
 Extrapolation should be considered in light of the totality of data (quality, non-clinical, and clinical data)\
 Immunogenicity may differ among indications; therefore, extrapolation of immunogenicity from the studied indication / route of administration to other uses of the reference medicine should be justifiedPharmacovigilance Clinical safety of biosimilars must be closely monitored on an ongoing basis following approval, including continued benefit-risk assessment*EEA* European Economic Area, *EMA* European Medicines Agency, *IV* intravenous, *PK* pharmacokinetic, *PD* pharmacodynamic, *SC* subcutaneous

The development of biosimilars is a systematic, iterative process involving several stages. Initially, the reference medicine is fully characterized to define its critical features and inherent variability, which are used as a "baseline" for development of the biosimilar \[[@CR11]\]. A series of analytical assessments are conducted to ensure that the biosimilar has the same structural and functional properties as the reference medicine (Table [1](#Tab1){ref-type="table"}) \[[@CR11], [@CR12]\]. Then may follow preclinical studies, for example, pharmaco-toxicological evaluations. Human clinical development usually includes phase 1 pharmacokinetics (PK) and pharmacodynamics (PD) studies to show bioequivalence, ideally in healthy volunteers. Finally, typically one confirmatory clinical phase 3 trial in a sensitive patient population is conducted to ensure that there are no meaningful differences in efficacy and safety between the biosimilar and reference medicines (Table [1](#Tab1){ref-type="table"}).

Regulatory authorities will approve a proposed biosimilar only if similarity to the reference medicine is established based on the totality of evidence from the analytical, preclinical, and clinical development program \[[@CR8], [@CR13]\]. In some cases, bridging studies may be required by regulatory authorities to allow acceptance of development data generated with reference biologics licensed in a different territory \[[@CR14]\]. When biosimilar comparability has been demonstrated, extrapolation to other indications of the reference medicine could be acceptable but needs to be scientifically justified and considered in light of all available (analytical, nonclinical, and clinical) data \[[@CR9], [@CR13], [@CR15]\]. The scientific principles behind extrapolation of data are not new for biosimilars; they also apply to the comparison of approved products, before and after a change in the manufacturing process \[[@CR16]\].

Were Initial Concerns Raised by the Nephrology Community About Biosimilars Justified? {#Sec3}
-------------------------------------------------------------------------------------

Several concerns were initially raised by the nephrology community in relation to epoetin biosimilars, particularly regarding variability, quality, and safety.

### Variability and Quality {#Sec4}

Initial concerns that biosimilars may be highly variable and/or of substandard quality, compared with the licensed reference medicine, do not appear to be justified. A small degree of variability is common with any biological medicine, whether a reference medicine or a biosimilar, and batches are never identical to each other \[[@CR16], [@CR17]\]. It is interesting to note that any biological medicine will probably be modified several times throughout its life cycle \[[@CR18]\]; such modifications typically arise due to changes in the manufacturing process. Such changes are small in most cases but can also be large (such as, in some cases, cell-line changes \[[@CR19]\]). Therefore, current widely used biological medicines will technically not be identical to the originally approved version \[[@CR16]\]. Regulatory authorities therefore require comparability data for the pre- and post-change product to ensure that any changes have no adverse effect on quality, clinical efficacy, and clinical safety \[[@CR20]\]. This is known as a "comparability exercise", the underlying principles of which form the basis of the concept of biosimilarity.

Extensive characterization is conducted to establish that any microheterogeneity between a biosimilar and its reference medicine does not impact on clinical efficacy, or safety and immunogenicity. A recent study compared the quality and batch-to-batch variability of marketed epoetin reference medicines, Eprex^®^/Erypo^®^ (Janssen-Cilag, High Wycombe, UK) and NeoRecormon^®^ (epoetin beta; Roche Registration Limited, Welwyn Garden City, UK), and two biosimilars, Binocrit^®^ (Sandoz GmbH, Kundl, Austria) and Retacrit^®^ (Hospira UK Limited, Maidenhead, UK) \[[@CR21]\]. All epoetin products were found to be of high quality, although there was some degree of variation among products and batches, confirming the "similar but not identical" paradigm of biologicals. Of note, biosimilar manufacturers are able to take advantage of state-of-the-art methodologies, which may not be used by manufacturers of reference medicines due to the financial and regulatory impact of changing from older processes \[[@CR22]\].

In another study, the quality of Binocrit^®^ and Retacrit^®^ was found to be equal to that of the reference medicine, with partially lower levels of some impurities \[[@CR23]\]. Unlike EMA-approved biosimilar epoetins, there are no assurances on the quality of "copy" biological epoetins manufactured in countries lacking rigorous regulations and standardized manufacturing processes \[[@CR24], [@CR25]\].

Qualitative and quantitative analysis of the reference epoetin alfa and two of its biosimilars revealed chemical differences were found only at the level of isoforms containing N-glycosylation. However, functional *in vivo* and *in vitro* studies found no significant differences and confirmed the effective structural and functional similarity of the reference epoetin alfa and the biosimilars \[[@CR26]\].

Comparisons of the epoetin area under concentration--time curve (AUC) ratios demonstrate the pharmacokinetic equivalence of the reference epoetin alfa and biosimilar epoetins. The area under total concentration curve from 0--36 h at steady state (AUC~τ~) ratio of Binocrit^®^ compared with the reference epoetin alfa was 89.2% \[90% confidence interval (CI) 82.5--96.2\] \[[@CR27]\]. An AUC ratio of 114.98% (90% CI 110.49--119.66) was found between Binocrit^®^ samples from the original production site and an additional production site. However, this level of variability falls within the standard bioequivalence boundaries of 80--125% \[[@CR28]\]. This study also included comparisons of Binocrit^®^ samples with a US-marketed epoetin alfa (Epogen^®^, Amgen, Thousand Oaks, CA, USA) and the European-marketed reference epoetin alfa (Eprex^®^/Erypo^®^). An equivalent pharmacodynamic response was achieved with all compared epoetin alfa products, as confirmed by the hemoglobin AUEC ratio's 90% CI falling within the predefined acceptance margins of 96.8--103.2% \[[@CR28]\].

### Safety, Including Immunogenicity {#Sec5}

As for any biological medicine, a key safety concern for biosimilars is immunogenicity. In rare cases, antibodies generated against exogenous erythropoietin may elicit hypersensitivity reactions, which can have a neutralizing effect and lead to pure red cell aplasia (PRCA) \[[@CR17]\]. Human safety data are required for EMA approval of all biosimilars, including biosimilar epoetins \[[@CR17]\], with at least 12 months of comparative immunogenicity results, using a validated and highly sensitive assay for anti-erythropoietin antibody detection \[[@CR10]\]. None of the studies in the clinical program with HX575 or SB309, administered intravenously (IV), reported the presence of neutralizing anti-erythropoietin antibodies or any signs or symptoms consistent with PRCA \[[@CR29], [@CR30]\].

Subcutaneous (SC) administration of Eprex^®^/Erypo^®^ in patients with CKD was contraindicated in the European Union (EU), between 2002 and 2006, after increased reports of PRCA \[[@CR31]\]. After 2006, the incidence of PRCA dropped substantially when the manufacturer replaced uncoated with coated rubber stoppers and reinforced the cold chain. SC use was subsequently reinstated, allowing a comparative study of SC HX575 and Eprex^®^/Erypo^®^ in renal anemia to be conducted; however, two patients developed neutralizing anti-erythropoietin antibodies following SC administration of HX575 in this trial \[[@CR32]\]. A thorough root-cause analysis indicated that immunogenic reactions were precipitated by increased tungsten exposure and associated protein aggregation in pre-filled syringes with a small number of study drug batches \[[@CR33], [@CR34]\]. The manufacturing process was subsequently improved to reduce tungsten levels (introduction of low-tungsten syringes) and, following the completion of an open-label, single-arm study in pre-dialysis and dialysis patients in which no patients developed neutralizing antibodies \[[@CR35]\], HX575 was approved by the EMA for SC administration in the nephrology indication in March 2016 \[[@CR36]\].

Several cases of PRCA have been reported following the use of "copy" biological epoetins in Latin America and Asia. These alternative biologic products vary in composition and typically do not follow a rigorous development and approval process, such as the one mandated by the EMA in Europe \[[@CR37], [@CR38]\]. When cases of PRCA do occur, identifying the treatment that caused the condition is a potential issue in patients who have been switched from one drug to another. In addition to the rigorous development and approval process for biosimilars in Europe, post-marketing and risk management pharmacovigilance plans must be submitted for biosimilar epoetins \[[@CR39]\]. After biosimilars are approved, companies are also required to submit periodic safety reports.

There have also been concerns raised about potential safety risks associated with switching to and from biosimilar products \[[@CR40]\]. A retrospective drug utilization study conducted in Italy quantified the occurrence of switching between different epoetins \[[@CR41]\]. The probability of switching was associated with the duration of treatment: about 15% of users switched within 12 months and almost 25% within 2 years of observation. Switching was not restricted to the replacement of reference epoetins with biosimilar epoetins but also extended to products that have not been directly compared in clinical studies. The authors concluded that the level of switching may provide reassurance to physicians when taken together with other sources of comparative evidence \[[@CR41]\]. A review of data from clinical trials, pharmacovigilance databases, and an overview of the literature on the frequency of switching, assessed both switching between reference medicines within the same product class and switching to and from biosimilars. No evidence was found to suggest that switching to and from different biologicals leads to safety concerns \[[@CR40]\].

A retrospective analysis of stable adult hemodialysis patients (*n* = 326) has reported that switching from the reference epoetin to a biosimilar may incur a dose penalty \[[@CR42]\]. However, this report is inconsistent with other published data. These include a population-based analysis of real-world data from ambulatory patients (*n* = 6117) with CKD undergoing maintenance hemodialysis \[[@CR43]\], and a large post-approval study of IV HX575 in patients (*n* = 1695) with CKD \[[@CR44]\].

Summary of Clinical Data Available for Biosimilar Epoetins in Europe {#Sec6}
--------------------------------------------------------------------

Two biosimilar epoetins (marketed under five brand names) have been approved by the EMA and are currently available in Europe (Table [2](#Tab2){ref-type="table"}). HX575 is a biosimilar version of Eprex^®^/Erypo^®^ and, in 2007, became the first biosimilar epoetin to be approved in Europe. HX575 has the same international non-proprietary name (INN) as epoetin alfa and is marketed as Binocrit^®^ (Sandoz GmbH, Kundl, Austria), Epoetin alfa HEXAL^®^ (Hexal AG, Holzkirchen, Germany), and Abseamed^®^ (Medice Arzneimittel Pütter GmbH & Co. KG, Iserlohn, Germany). SB309 is a biosimilar epoetin that also has Eprex^®^/Erypo^®^ as its reference medicine but has the INN epoetin zeta. It is marketed as Retacrit^®^ (Hospira UK Limited, Maidenhead, UK) and Silapo^®^ (Stada Arzneimittel AG, Bad Vilbel, Germany).Table 2Erythropoiesis-stimulating agents currently available in EuropeCharacteristicCompanySandoz,\
Hexal,\
Medice ArzneimittelHospira, STADATevaJ&J\
(Janssen-Cilag)RocheAmgenRocheINNEpoetin alfa (biosimilar)Epoetin zeta (biosimilar)Epoetin thetaEpoetin alfaEpoetin betaDarbepoetin alfaMethoxy polyethylene glycol-epoetin betaYear of first launch2007200820101989199020012007Route of administrationIV, SCIV, SCIV, SCIV, SCIV, SCIV, SCIV, SC*INN* international non-proprietary name, *IV* intravenous, *SC* subcutaneous

Figure [1](#Fig1){ref-type="fig"} gives an overview of key clinical studies performed with biosimilar epoetins in Europe. Complementing the *in vitro* and preclinical characterization, and PK/PD studies, these clinical trials provided the additional data needed to reassure European authorities that HX575 and SB309 were sufficiently similar to reference epoetin to warrant approval as biosimilar agents.Fig. 1Key clinical studies of biosimilar epoetins in Europe \[[@CR29], [@CR30], [@CR35], [@CR44]--[@CR50]\]. *PK* pharmacokinetic, *PD* pharmacodynamic, *IV* intravenous, *SC* subcutaneous, *CKD* chronic kidney disease, *HD* hemodialysis

Several phase 1 PK and PD studies have been conducted with SB309 and HX575, and these have all shown profiles that are similar to the reference medicine \[[@CR29], [@CR30]\]. Two phase 3 randomized trials compared the efficacy of IV SB309 and reference epoetin alfa in patients with CKD-induced anemia and therapeutic equivalence was demonstrated in both studies \[[@CR45], [@CR46]\]. In one of these studies, 609 patients with CKD and anemia (hemoglobin \[Hb\] \< 9 g/dl) received either SB309 or Eprex^®^/Erypo^®^ IV for 24 weeks \[[@CR45]\]. Mean (standard deviation \[SD\]) Hb concentration over the last 4 weeks of treatment was 11.61 (1.27) g/dl with SB309 and 11.63 (1.37) g/dl with reference epoetin alfa (95% CI − 0.25 to 0.20). The most commonly reported adverse events (AEs; \> 5% of patients) by System Organ Class were infections and infestations (12.5% and 12.8% of patients treated with SB309 and reference epoetin alfa, respectively) and vascular disorders (8.5 and 8.9%, respectively). No patients developed neutralizing anti-erythropoietin antibodies. After receiving authorization for IV administration, a later premarket authorization randomized trial assessed the therapeutic equivalence of SC SB309 and reference epoetin alfa \[[@CR47]\]. This study showed therapeutic equivalence in maintaining target Hb levels and in safety profiles.

For HX575, a phase 3 maintenance study was conducted versus reference medicine in adult dialysis patients and therapeutic equivalence was demonstrated \[[@CR30], [@CR48]\]. Hemodialysis patients with Hb levels of 10.0--13.0 g/dl received either HX575 or Eprex^®^/Erypo^®^ IV, one to three times per week for 28 weeks \[[@CR48]\]. Mean changes in Hb levels were 0.15 (0.09) g/dl with HX575 and 0.06 (0.12) g/dl with reference epoetin alfa, with a difference between groups of 0.08 g/dl (95% CI − 0.17 to 0.34). The long-term safety profile of HX575 was similar to that of the reference epoetin alfa. No patients developed neutralizing anti-erythropoietin antibodies. In the open-label, single-arm registration study of SC HX575 in 416 pre-dialysis and dialysis patients, HX575 was effective in managing anemia, regardless of whether they had previously been treated with epoetins, with no clinical signs of immunogenicity or hypersensitivity with SC administration \[[@CR35]\].

Several post-authorization studies have and are being conducted to provide long-term effectiveness and safety data, particularly the incidence of less frequently experienced AEs, which may not be detected in shorter, smaller registration studies. One example is the post-marketing EPO-PASS study of IV HX575, involving more than 1700 patients with renal anemia \[[@CR44]\]. The study period covered 770 patient-years. The observed AE profile was in line with expectations for this patient population. No subject developed anti-epoetin antibodies. Thrombotic vascular events were reported in 11.9% of patients (0.2612 per patient-year). Tumor incidence was 1.4% (0.0299 per patient-year). Mean Hb levels were effectively maintained between 11.2 and 11.3 g/dl following the conversion from a broad spectrum of pre-study, erythropoiesis-stimulating agent (ESA) treatments with stable overall mean IV HX575 doses. The proportion of patients within the Hb target range increased from 57.5% at baseline to 66.8% at study end.

Safety findings have been reported for the PASCO I study with IV SB309 in 1634 patients with renal anemia over a 1-year study observation period \[[@CR50]\]. The frequency of AEs of special interest was comparable with data for other existing epoetin products: clotting of artificial kidney, 9.8%; lack of efficacy, 2.3%; cerebrovascular events, 1.8%; myocardial infarction, 1.7%; acute myocardial infarction, 1.2%; clinically relevant hyperkalemia, 0.4%; deep vein thrombosis, 0.2%; convulsion, 0.2%; hypertensive encephalopathy, 0.1%; and pulmonary embolism, 0.1%. No patients were reported as having anaphylactoid reactions, angioedema, erythropoietin-neutralizing antibodies, or PRCA.

Data and experience continue to accumulate for biosimilar epoetins in renal anemia. A population---based study compared the effects of the reference epoetin Eprex^®^/Erypo^®^ with three biosimilars (Binocrit^®^, Abseamed^®^ and Retacrit^®^) in 583 patients with CKD. There was no statistically significant difference among the reference medicine and biosimilars in dose dispensed, and the efficacy and safety of the epoetin biosimilars were found to be equivalent to that of the reference medicine \[[@CR51]\]. In another population---based observational study of 8161 patients with CKD, no differences between the reference medicine and biosimilars were found with regard to the risk of all---cause mortality, blood transfusion, major cardiovascular events and blood dyscrasia \[[@CR52]\]. Taken together, these data provide evidence of effectiveness and reassurance that there have been no unexpected safety signals with the real-world use of biosimilar epoetins.

What Can Be Learned from the European Experience? {#Sec7}
-------------------------------------------------

The first biosimilar product was approved in the EU in 2006, with the first biosimilar epoetin following in 2007 \[[@CR53]\]. Despite some initial reluctance, the adoption of biosimilar epoetins continues to grow, although there is some variation in uptake across countries \[[@CR25], [@CR38]\]. In ten European countries (seven Western and three Central/Eastern), biosimilar epoetins have a market share of \> 25%, including five countries (three Western and two Central/Eastern) at ≥ 50%. The variation in uptake is probably due to different cost pressures across the healthcare systems, different cost-containment measures, and the presence or absence of healthcare policies driving biosimilar adoption \[[@CR38]\]. For example, in France there was no pressure to reduce costs associated with ESA therapy up until the end of 2013. Since then, the cost of ESAs has been included in dialysis fees and this may result in greater adoption of biosimilar medicines.

It has been estimated that the availability of biosimilar ESAs in Germany provided a saving of €60 million during their first year on the market. This saving comprised the lower price of the biosimilars and also price reductions for reference medicines \[[@CR38], [@CR54]\]. The same study projected potential savings through biosimilar use of €8 billion in Germany alone up to 2020.

Following EU availability, biosimilar epoetins have been approved in Australia in 2010 and in New Zealand in 2013 \[[@CR39]\]. In the USA, guidelines on scientific and quality considerations in demonstrating biosimilarity were issued by the Food and Drug Administration (FDA) in 2015, following the enactment of the Biologics Price Competition and Innovation Act in 2010 \[[@CR13], [@CR55], [@CR56]\]. In general, the FDA has developed a similar biosimilar approval pathway as in the EU, involving clear demonstration that the biosimilar product is highly similar to an FDA-approved reference medicine and has no clinically meaningful differences in terms of safety and effectiveness. Only minor differences in clinically inactive components are permitted in biosimilar products. The FDA regulatory pathway also includes the option for a regulatory designation on interchangeability, which refers, in the USA, to the ability to automatically substitute a medicine at the pharmacy level, and which requires additional data for biosimilarity alone \[[@CR13]\]. Draft guidance on considerations in demonstrating interchangeability with a reference medicine was published in January 2017 \[[@CR57]\]. EU regulators have stated that EU-approved biosimilars are considered medically interchangeable; this refers, in the EU, to the practice of changing one medicine for another that is expected to achieve the same clinical effect in a given clinical setting and in any patient, with the agreement of the prescriber \[[@CR58]\]. In the EU, decisions on automatic substitution between a biological reference medicine and its biosimilar is upon the mandate of individual member states \[[@CR10], [@CR39]\].

The first biosimilar product to be approved by the FDA under the new regulatory pathway was Zarxio^®^ (filgrastim-sndz; Sandoz GmbH, Kundl, Austria) in March 2015, with approval granted for all the same indications as the reference medicine, Neupogen^®^ (Amgen Europe B.V, Breda, The Netherlands) \[[@CR59]\]. The expiry of patents in 2014 potentially opens the USA market to biosimilar epoetins; submissions have been made to the FDA, and the Oncology Drugs Advisory Committee (ODAC) recently recommended approval of a proposed biosimilar epoetin alfa \[60\]. If approved, the provision of adequate education to payers, healthcare professionals, and patients regarding the biosimilar concept will be important for their acceptance \[[@CR56]\]; however, reassurance may be provided from the decade of experience gained in Europe for biosimilar epoetins.

Summary {#Sec8}
=======

Biosimilars, including biosimilar epoetin alfas, have now been available in Europe for 10 years and their use is becoming more widespread. As of April 2016, Binocrit^®^ has generated more than 400,000 patient-years of experience worldwide (in CKD and chemotherapy-induced anemia) \[[@CR31]\]. These agents are approved only if extensive analytical and clinical testing demonstrates comparable quality, safety, and efficacy to the reference medicine. Real-world studies provide further evidence that biosimilar epoetins are an effective and well tolerated option for the treatment of renal anemia, with ongoing pharmacovigilance and observational studies, monitoring for any unexpected long-term signals that have not been identified in clinical development studies.

Europe has led the way with their rigorous biosimilar approval pathway; other countries have used the lessons learned in Europe to develop their own processes and, as such, biosimilar epoetins are now available across many countries and regions. Expansion into the USA market is now likely, following the recent positive opinion of the FDA ODAC on a proposed biosimilar epoetin alfa; assuming full approval follows, additional experience will be gained in this large market, where the proportion affected by renal anemia is high. As the evidence and experience with these products increase, many of the initial concerns are being alleviated. Nephrologists can be increasingly confident that biosimilars offer high-quality, affordable, effective alternatives to existing reference medicines used to treat anemia, and may help yield cost savings and improve patient access.
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